Medgenics has elected Isaac Blech to its board of directors, bringing the number of board members to seven. Mr Blech has served on the company's strategic advisory board since February 2011 and has invested $7 million in the company over the past year. He has founded seven companies, including Celgene, Genetic Systems and Nova Pharmaceuticals.
Isaac Blech joins Medgenics' board
Medgenics has elected Isaac Blech to its board of directors, bringing the number of board members to seven. Mr Blech has served on the company's strategic advisory board since February 2011 and has invested $7 million in the company over the past year. He has founded seven companies, including Celgene, Genetic Systems and Nova Pharmaceuticals.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
• By
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
• By
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.